DRMA vs. FLGC, COCP, PMN, GELS, BFRG, ALLR, VYNE, RLYB, ACXP, and PRPH
Should you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Flora Growth (FLGC), Cocrystal Pharma (COCP), Promis Neurosciences (PMN), Gelteq (GELS), Bullfrog AI (BFRG), Allarity Therapeutics (ALLR), VYNE Therapeutics (VYNE), Rallybio (RLYB), Acurx Pharmaceuticals (ACXP), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry.
Dermata Therapeutics vs. Its Competitors
Flora Growth (NASDAQ:FLGC) and Dermata Therapeutics (NASDAQ:DRMA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.
Flora Growth currently has a consensus price target of $4.00, suggesting a potential upside of 529.92%. Dermata Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 350.45%. Given Flora Growth's higher possible upside, analysts plainly believe Flora Growth is more favorable than Dermata Therapeutics.
36.0% of Flora Growth shares are held by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are held by institutional investors. 12.6% of Flora Growth shares are held by company insiders. Comparatively, 18.5% of Dermata Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Dermata Therapeutics has lower revenue, but higher earnings than Flora Growth. Flora Growth is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Flora Growth has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500.
In the previous week, Flora Growth had 4 more articles in the media than Dermata Therapeutics. MarketBeat recorded 4 mentions for Flora Growth and 0 mentions for Dermata Therapeutics. Flora Growth's average media sentiment score of 0.79 beat Dermata Therapeutics' score of 0.00 indicating that Flora Growth is being referred to more favorably in the media.
Dermata Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -24.85%. Flora Growth's return on equity of -216.49% beat Dermata Therapeutics' return on equity.
Summary
Flora Growth beats Dermata Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Dermata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dermata Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DRMA) was last updated on 7/4/2025 by MarketBeat.com Staff
